24×7 Emergency Care

1-8-31/1, Minister Road, Secunderabad, Telangana 500003

EMERGENCY:For urgent neurosurgical or oncological assessment — sudden neurological deterioration, severe headache, seizure, or new deficit after treatment —call040-46324365immediately — 24 hours, 7 days— 24/7

GAMMA KNIFE RADIOSURGERY · BENEFITS & SAFETY

Gamma Knife Radiosurgery — Benefits, Safety Profile, and Clinical Evidence at KIMS Hyderabad

What Gamma Knife achieves, what risks it carries, when it is preferred over surgery and when surgery is preferred — an honest, evidence-based assessment from the KIMS Gamma Knife team, Secunderabad, Hyderabad.

View Our Specialists

The 6 benefits of Gamma Knife vs surgery — with mechanisms: (1) No surgical complications: no wound infection, haematoma, CSF leak, meningitis, anaesthetic reaction, or pulmonary embolism. (2) Sub-millimetre precision: dose drops dramatically within 2–3 mm, enabling precise constraints on adjacent critical structures. (3) Single-day procedure: arrival to discharge in 4–6 hours vs a 5–10 day stay for brain surgery. (4) Surgically inaccessible targets: 192 beams penetrate from all angles — depth carries no added risk. (5) No general anaesthesia: eliminated for elderly, cardiac, respiratory, obese, and sleep-apnoea patients. (6) 50+ years of evidence: 10- and 15-year follow-up data for meningioma and AVM.
When Gamma Knife is preferred over surgery: Deep, eloquent, brainstem, and skull base tumours where surgery carries high risk of neurological deficit · Elderly or medically frail patients for whom anaesthesia or open surgery is prohibitive · Patients on anticoagulation or antiplatelet therapy who cannot safely stop medication · Tumours where surgery makes cranial nerve or vascular injury inevitable (cavernous sinus and petroclival meningioma) · Patients who decline surgery · Post-surgical residual planned for Gamma Knife adjuvant.
When surgery is preferred over Gamma Knife: Large tumours (>3–3.5 cm): insufficient dose fall-off · Mass effect or hydrocephalus requiring immediate decompression: Gamma Knife does not decompress · Tissue diagnosis needed urgently: Gamma Knife does not provide tissue · Tumour type that does not respond to radiation (most primary gliomas; lymphoma needing steroids immediately) · Young patients with long life expectancy where the very low secondary-malignancy risk is weighed over decades.
The safety record — 50 years and more than one million patients: Gamma Knife has been performed in over one million patients since 1968 — the most extensive long-term safety data of any brain radiosurgery technique. Patients are not radioactive after treatment — no radiation exposure to companions or family.
Radiation necrosis — the most important late complication: Radiation necrosis is an area of cell death within previously treated tissue caused by the cumulative radiation dose. It occurs in 2–5% of brain metastasis patients (lower for other indications), typically 6–24 months after treatment. It can mimic tumour progression on imaging — MR spectroscopy, perfusion imaging, or FDG-PET can differentiate. Management: dexamethasone to reduce oedema; bevacizumab for steroid-refractory cases; surgical resection rarely needed. Most cases resolve or stabilise with treatment. Unlike conventional radiotherapy and other radiosurgery platforms, Gamma Knife produces no skin changes and no hair fall. Radiation necrosis with Gamma Knife is significantly less common compared to other radiosurgery platforms, because of the highly conformal dose distribution that minimises radiation to surrounding healthy brain tissue.
Emergency: Sudden neurological deterioration, severe headache, seizure, or new deficit after treatment — call 040-46324365 immediately (24×7).

Fact	Details
Safety record	>1 million patients since 1968 · 50+ years of follow-up data for meningioma and AVM
6 key benefits	No surgical complications · Sub-millimetre precision (dose drops within 2–3 mm) · Single-day procedure · Surgically inaccessible targets · No general anaesthesia · 50+ year evidence base
Prefer Gamma Knife over surgery	Deep/eloquent/skull-base tumours · Elderly/frail patients · Anticoagulated patients · Cavernous sinus and petroclival meningioma · Post-surgical residual adjuvant
Prefer surgery over Gamma Knife	Tumour >3.5 cm · Mass effect requiring decompression · Tissue diagnosis urgently needed · Non-radiation-sensitive tumour type · Young patient with very long life expectancy
Most common side effects	Frame pin-site headache (procedure day) · Fatigue (1–2 days) · Radiation necrosis 2–5% (brain metastases)
Radiation necrosis	2–5% of brain metastasis patients · 6–24 months after treatment · Managed with dexamethasone and/or bevacizumab · Distinguished from recurrence by MR spectroscopy/PET · No skin changes and no hair fall · Significantly less common than with other radiosurgery platforms (highly conformal dose distribution)
Contact	040-44885000 · Second opinions welcome · No referral required · 040-46324365 (24×7 emergency)

About This Page

Honest, Evidence-Based — Both the Benefits and the Limitations

Patients and families considering Gamma Knife deserve a direct, evidence-based account of what the treatment achieves, what risks it carries, and how those risks compare to the alternatives. This page provides that account — without underplaying the real side effects that some patients experience, and without overstating the benefits beyond what the evidence supports. Both the benefits and the limitations are described specifically and honestly.

Book a Consultation

Speak directly with the KIMS Gamma Knife team. Second opinions welcome. No referral required.

040-44885000Email: neuroscience@kimshospitals.com

★ Definition — Is Gamma Knife Radiosurgery Safe?

A 50-Year Safety Record

Yes — Gamma Knife radiosurgery has been performed in over one million patients since 1968 and has a well-characterised safety profile. The risk of treatment-induced secondary cancer is extremely low, and the procedure carries none of the risks of open surgery: no infection, no bleeding, no anaesthetic complications, and no surgical trauma.

The Six Benefits at a Glance

The Benefits Stack of Gamma Knife at KIMS

A one-card summary of each benefit — followed by the full clinical detail in the section below.

No Incision, No Craniotomy

Benefit 1: No Open Surgery

No scalp incision, skull opening, or brain manipulation — the wound infection, haematoma, CSF leak, meningitis, anaesthetic, and pulmonary embolism risks of surgery do not apply. Especially valuable for elderly, cardiac, respiratory, and anticoagulated patients.

Steep Dose Fall-Off

Benefit 2: Sub-millimetre Precision

Dose drops dramatically within 2–3 mm of the target boundary — enabling treatment of targets adjacent to the optic nerve, cochlea, facial nerve, and brainstem with precise dose constraints on each critical structure.

Day Case

Benefit 3: Single-Day Procedure

Most treatments complete in one day — versus 5–10 day hospital stay for brain surgery and 20–30 daily sessions over 4–6 weeks for conventional radiotherapy.

Deep Brain Targets

Benefit 4: Reaches Surgically Inaccessible Targets

Beams penetrate the skull and reach the brainstem, basal ganglia, thalamus, pineal region, and deep eloquent cortex with equal ease regardless of depth.

Local Anaesthesia Only

Benefit 5: No General Anaesthesia

Stereotactic frame placed under local anaesthetic; patient fully conscious throughout. Eliminates anaesthetic risk for elderly, cardiac, respiratory, and obese / sleep-apnoea patients.

>1 Million Patients Since 1968

Benefit 6: 50+ Years of Evidence

10- and 15-year follow-up data for meningioma and AVM from multiple large series — the most extensive long-term evidence base of any radiosurgery technology.

Section 1

The Benefits of Gamma Knife Radiosurgery

Benefit 1: No incision, no open surgery, no surgical complications

The most obvious and most important advantage of Gamma Knife over open surgery is that it involves no scalp incision, no skull opening, and no brain manipulation. The complications that are specific to surgery — wound infection, haematoma, CSF leak, meningitis, adverse anaesthetic reactions, pulmonary embolism from immobility — are not applicable to Gamma Knife. For elderly patients, patients with significant cardiac or respiratory disease, patients on anticoagulation, and patients with poor performance status, the surgical risk can be prohibitively high while the Gamma Knife risk is very low.

Benefit 2: Sub-millimetre precision — sparing adjacent critical structures

The steep dose fall-off at the target margin of Gamma Knife (the dose drops dramatically within 2–3 mm of the target boundary) allows treatment of targets immediately adjacent to critical structures — the optic nerve, the cochlea, the facial nerve, the brainstem — that would be at high risk in open surgery. A meningioma in the cavernous sinus, immediately surrounding the internal carotid artery and cranial nerves III, IV, V, and VI, can be treated with Gamma Knife with precise dose constraints on each nerve — an approach that surgery cannot match.

Benefit 3: Single-day procedure for most patients

Most Gamma Knife treatments are completed in a single day, with the patient arriving in the morning and going home in the afternoon or evening. Compared to: brain surgery (5–10 day hospital stay) · Conventional radiotherapy (20–30 daily sessions over 4–6 weeks). The single-day nature of Gamma Knife has obvious practical advantages for patients — less time off work, no extended hospital admission, faster return to normal life, and dramatically lower total treatment cost when hospital stay is factored in.

Benefit 4: Treats surgically inaccessible locations

Deep brain structures — the brainstem, basal ganglia, thalamus, pineal region, and deep eloquent cortex — are surgically inaccessible or accessible only with very high risk. Gamma Knife beams penetrate the skull and reach deep brain targets with equal ease regardless of depth. A metastasis in the brainstem that cannot be safely operated can be treated with Gamma Knife using precisely dosed radiation with tight margins.

Benefit 5: No anaesthesia-related risk for most patients

General anaesthesia carries real risks, particularly for elderly patients, those with cardiac disease, respiratory disease, or obese patients with sleep apnoea. Gamma Knife does not require general anaesthesia: the stereotactic frame is placed under local anaesthetic, and the patient is fully conscious throughout treatment. For patients who are genuinely at high anaesthetic risk, this is one of the most clinically significant advantages of Gamma Knife.

Benefit 6: Proven, long-term evidence base

With over one million patients treated since 1968, Gamma Knife has the most extensive long-term clinical evidence base of any radiosurgery technology. The 10-year and 15-year follow-up data for meningioma and AVM are available from multiple large series, providing a level of evidence that allows realistic, evidence-based counselling.

Section 2

The Risks and Side Effects — Honest Assessment

Gamma Knife radiosurgery is not without risk. The side effects are different from surgery but they are real and should be clearly understood before treatment.

Acute side effects (during and immediately after treatment)

Headache: mild to moderate, from the frame pin sites and rarely from treatment-induced brain oedema. Usually responds to paracetamol and resolves within 24–72 hours. Rate: 30–50% (mild) · Nausea: from the procedure, the frame, or pre-medications. Rate: 5–15% · Fatigue: most patients feel tired for 1–3 days. Rate: 40–60% · Seizure: rare, most likely in patients with pre-existing seizure history or large tumours. Rate: <1–2% · Worsening of pre-existing neurological symptoms (from treatment-induced oedema): 5–10%, typically transient and responding to steroid treatment.

Subacute side effects (weeks to months after treatment)

Radiation oedema and pseudo-progression: the treated tumour or adjacent brain may swell transiently 1–6 months after Gamma Knife, causing temporary worsening of neurological symptoms. This occurs in approximately 10–20% of patients and is managed with dexamethasone. It usually resolves within weeks. In some cases (particularly large or aggressive tumours), pseudo-progression can be difficult to distinguish from tumour growth — which is why follow-up MRI at multiple time points is important. Facial numbness after trigeminal neuralgia treatment: 10–20% of patients develop some degree of permanent numbness in the trigeminal nerve distribution — accepted as an expected side effect of the high-dose nerve targeting technique.

Long-term side effects (months to years)

Radiation necrosis: the development of dead and inflammatory tissue at the treatment site, occurring in 2–5% of patients 1–3 years after treatment. Radiation necrosis can mimic tumour recurrence on imaging and may cause neurological symptoms. Management: bevacizumab (anti-VEGF antibody) has become the standard treatment for symptomatic radiation necrosis, with 70–80% response rates. Surgical excision is rarely needed. Hypopituitarism after pituitary adenoma treatment: 20–30% at 5 years — requiring hormone replacement.

Side Effect Frequency Table

Gamma Knife Side Effects — Frequency, Duration, and Management

The comparison matrix below summarises the side effects associated with Gamma Knife treatment, including their frequency, duration, and management pathway at KIMS.

Side Effect

Frequency

Duration

Management

Headache (frame-related)

30–50%

1–3 days

Paracetamol

Fatigue

40–60%

1–3 days

Rest

Nausea

5–15%

24h

Antiemetics

Transient worsening of symptoms

5–10%

Weeks

Dexamethasone

Radiation oedema / pseudo-progression

10–20%

Weeks–months

Dexamethasone · Bevacizumab

Radiation necrosis (symptomatic)

2–5%

Months–years

Bevacizumab · Rarely surgery

Facial numbness (trigeminal neuralgia only)

10–20%

Permanent in some

Accepted trade-off for pain relief

Hypopituitarism (pituitary SRS only)

20–30% at 5 years

Permanent

Hormone replacement therapy

New neurological deficit

<2–3%

Variable

Depends on deficit and location

Secondary radiation-induced tumour

Very rare

Years–10+ years

Rare · Manageable when identified

Section 3

Gamma Knife vs Open Surgery — When Each is Better

The comparison matrix below summarises when Gamma Knife or open surgery is preferred for a specific tumour, location, and patient profile.

Clinical Situation

Preferred Approach

Reason

Brain metastasis ≤3 cm, no mass effect

Gamma Knife (SRS)

Equivalent survival to surgery, same-day procedure

Single brain metastasis with mass effect and oedema

Surgery + post-op SRS

Decompression relieves symptoms; SRS controls residual cavity

Small meningioma, skull base, elderly patient

Gamma Knife

No surgical risk; equivalent long-term control

Large meningioma causing significant symptoms

Surgery first, +/– GK for residual

Decompression provides symptom relief GK cannot

Trigeminal neuralgia, not fit for surgery

Gamma Knife

No anaesthetic required; 70–80% pain relief

Trigeminal neuralgia, young and fit

MVD surgery (first choice)

Higher initial pain relief rate (90%) and better durability

Small deep AVM (≤2 cm), eloquent location

Gamma Knife

Surgery too risky; 90%+ obliteration rate for small AVMs

Large AVM (≥3 cm), ruptured, accessible

Surgery + embolisation · staged

GK obliteration rate low for large AVMs; surgery faster protection

Section 4

The Clinical Evidence Base — Key Published Studies

Brain metastases — RTOG 9508 and JCOG0504

RTOG 9508 (Andrews et al., Lancet 2004): In patients with 1–3 brain metastases, adding SRS boost to WBRT improved local control and performance status compared to WBRT alone. JCOG0504 (Kayama et al., J Clin Oncol 2022): SRS alone non-inferior to WBRT + SRS for 1–4 brain metastases in terms of overall survival, with significantly better neurocognitive outcomes in the SRS-alone arm. Brown et al. (JAMA 2016): Stereotactic radiosurgery alone superior to SRS + WBRT for preservation of cognitive function at 3 months, with equivalent intracranial tumour control.

AVM — ARUBA and the role of SRS

ARUBA trial (Mohr et al., Lancet 2014): Randomised trial showing medical management alone superior to intervention (surgery, SRS, or embolisation) for unruptured brain AVMs at 33 months — but with important limitations (short follow-up relative to AVM natural history; does not apply to ruptured AVMs). ARUBA's applicability to small, deep, eloquent-location AVMs where surgery is not feasible is debated. For ruptured AVMs and for surgically inaccessible AVMs, SRS remains the standard of care with 70–85% obliteration rates at 3 years.

Trigeminal neuralgia — Flickinger and Kondziolka series

Multiple series (Pittsburgh, Cleveland, Toronto) consistently show 70–80% initial pain relief and 50–60% long-term pain relief at 3 years after Gamma Knife for medically refractory trigeminal neuralgia. Facial numbness (the accepted side effect of nerve targeting) occurs in 10–20%. Repeat Gamma Knife for recurrence achieves similar rates of pain relief to the initial treatment.

Key Clinical Facts

What the Evidence Shows

Gamma Knife at KIMS is supported by 50+ years of published evidence and a side-effect profile that is well characterised. The following points summarise the most clinically significant facts every patient and family deserves to know before treatment.

Over 1 million Gamma Knife patients treated globally since 1968

Radiation necrosis occurs in 2–5% of patients 1–3 years after treatment — bevacizumab (anti-VEGF) achieves 70–80% response rates and has become the standard treatment

RTOG 9508 (Lancet 2004) and JCOG0504 (JCO 2022) established SRS for 1–4 brain metastases — Brown et al. (JAMA 2016) showed SRS alone preserves cognitive function significantly better than SRS + WBRT

ARUBA trial (Lancet 2014) addressed unruptured AVMs at 33 months only — for ruptured AVMs and surgically inaccessible AVMs, SRS remains the standard of care with 70–85% obliteration at 3 years

Hypopituitarism after pituitary adenoma SRS: 20–30% at 5 years — requiring hormone replacement therapy

Related Treatments

Explore related Gamma Knife and neurosurgical pages at KIMS Neuroscience:

Gamma Knife Radiosurgery Conditions Treated AVM Resection & Radiosurgery Trigeminal Neuralgia

Common Questions

Frequently Asked Questions

The risk of Gamma Knife radiosurgery causing a new (secondary, radiation-induced) brain tumour is extremely low in long-term follow-up studies. This risk exists because ionising radiation has a small probability of causing DNA mutations in normal cells that are traversed by the beams — but because the individual beam doses are very low (only the converging point receives the ablative dose), the exposure to surrounding normal brain is very limited. The lifetime risk of radiation-induced tumour after Gamma Knife is lower than the risk from conventional fractionated radiotherapy (which irradiates a larger brain volume at moderate doses) and is substantially lower than the tumour's natural history risk in most cases. To put it in context: the annual haemorrhage risk of an untreated AVM is 2–3% per year — approximately 50–70% over a lifetime. The benefit vastly outweighs the theoretical risk of a radiation-induced secondary tumour. Call 040-44885000.

For a meningioma where both options are offered, the decision depends on five specific factors: (1) Tumour size: meningiomas ≤3 cm in good surgical locations are candidates for either. Meningiomas >4–5 cm are generally better suited to surgery. (2) Location: skull base meningiomas (petroclival, cavernous sinus, clival) are often better treated with Gamma Knife, because surgery in these locations carries high risks of cranial nerve damage. Convexity meningiomas accessible to surgery with low risk are often better operated, particularly if they are symptomatic. (3) Symptoms: if the meningioma is causing significant symptoms from mass effect (headaches, focal deficit), surgery relieves the pressure immediately. Gamma Knife controls the tumour but does not decompress the brain acutely. (4) Age and medical fitness: elderly or medically unfit patients are better served by Gamma Knife, even for larger accessible tumours, if the surgical risk is prohibitive. (5) Long-term control: for WHO Grade I meningiomas, Gamma Knife achieves 93–97% control at 5 years — equivalent to complete surgical resection in most series. Incomplete surgical resection (grade II resection) has higher recurrence rates than Gamma Knife. At KIMS, this decision is made at the tumour board with both the neurosurgeon and radiation oncologist providing their assessment. Call 040-44885000.

Age is not a contraindication to Gamma Knife radiosurgery — and for elderly patients, Gamma Knife is often specifically preferred over surgery precisely because it avoids the anaesthetic and surgical complications that carry higher risk in this age group. At 80, with a small brain metastasis, the Gamma Knife eligibility assessment at KIMS focuses on: (1) Karnofsky Performance Status: is she able to perform normal daily activities with minimal assistance? (2) The number and size of the metastases: a small single or oligometastatic disease is ideal for Gamma Knife. (3) The status of the systemic (breast) cancer: is it being managed or controlled? (4) Whether the metastasis is causing significant symptoms — if she has severe mass effect or acute symptoms, a brief surgical decompression (under local anaesthetic in some cases) may precede Gamma Knife. The actual Gamma Knife treatment itself — lying in the unit for 15–25 minutes for a small metastasis — is well tolerated by patients in their 80s and 90s. The KIMS Gamma Knife team has treated many elderly patients with brain metastases and meningiomas with excellent tolerability. Call 040-44885000.

Yes — it is true that Gamma Knife is not 100% effective for every condition, and your neurosurgeon is right to set realistic expectations. Here are the specific limitations: (1) Tumour recurrence: approximately 5–10% of brain metastases and 3–7% of meningiomas will recur or continue to grow despite Gamma Knife, requiring additional treatment (repeat Gamma Knife, surgery, or conventional radiotherapy). (2) Failure to obliterate AVM: approximately 15–30% of medium-sized AVMs (2–3 cm) do not achieve complete obliteration after a single Gamma Knife session, requiring repeat treatment or surgery. (3) Incomplete hormonal control for pituitary tumours: 50–75% of secreting pituitary adenomas do not achieve hormonal remission with Gamma Knife alone, requiring continued medical therapy. (4) Size limitations: tumours that grow beyond 3 cm during the latency period may require surgery before or instead of repeat Gamma Knife. Gamma Knife is not a “set and forget” treatment — it requires follow-up imaging to confirm the response and identify the small proportion of patients who need additional intervention. At KIMS, this monitoring programme is built into the treatment plan from the beginning. Call 040-44885000.

A 50-Year Safety Record. An Evidence-Based Risk Profile. The Second Opinion is Always Welcome at KIMS Hyderabad.

A treatment with a 50-year safety record, a side effect profile lower than open surgery, and evidence-based outcomes for every indication it treats. At KIMS Hyderabad, the Gamma Knife team provides a full benefit-risk discussion before any treatment decision is made. Call 040-44885000. The second opinion is always welcome.

040-44885000

International enquiries: info@kimsneurosciences.com